XOMA Royalty
Update in progressXOMA (NGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
XOMA Royalty Corporation is a biotech royalty investor with activities in the United States, Switzerland, the Asia Pacific, and Australia. It holds economic rights to future milestone and royalty payments from commercial products and pre‑commercial therapeutics. The firm targets early‑ to mid‑stage assets (primarily Phase 1–2) licensed to sponsors and also acquires streams from late‑stage and commercial assets. Formerly XOMA Corporation, renamed July 2024; founded 1981; headquartered in Emeryville, California.
Company score
- Sentiment
- 0.35
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.05
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNGM
- LocationUnited States
- CEOMr. Owen P. Hughes Jr.
- Founded1981
- Employees14
- Websitewww.xoma.com
Identifiers
- ISINUS98419J2069
- FIGIBBG000BX4QV8
- LEI549300U6ZVYFCWNBJ613
- CUSIP98419J107
- CIK0000791908